Indian Journal of Sleep Medicine

Register      Login

VOLUME 11 , ISSUE 3 ( July-September, 2016 ) > List of Articles

REVIEW ARTICLE

Drug Therapy for Obstructive Sleep Apnoea

BNBM Prasad, Debajyoti Bhattacharyya, Yadvir Garg, Indramani Pandey

Keywords : Obstructive sleep apnoea (OSA), Drug therapy, Modafinil, Armodafinil, Positive airway pressure therapy (PAP).

Citation Information : Prasad B, Bhattacharyya D, Garg Y, Pandey I. Drug Therapy for Obstructive Sleep Apnoea. Indian Sleep Med 2016; 11 (3):95-98.

DOI: 10.5958/0974-0155.2016.00014.0

License: CC BY-SA 4.0

Published Online: 01-07-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Obstructive sleep apnea (OSA) is a common disorder that is characterized by obstructive apnoeas and hypopneas due to the repetitive collapse of the upper airway during sleep. A variety of effective behavioral and airway-specific therapies are available for the treatment of OSA, including weight loss, positive airway pressure therapy, oral appliances, and surgical procedures. Behavior modification is indicated for most patients who have OSA. This includes losing weight, exercising, abstaining from alcohol, and avoiding certain medications. For patients with severe OSA, positive airway pressure is recommended as initial therapy. Oral appliance may be tried for patients with mild to moderate OSA. Surgical therapy is usually for the surgically correctable obstructing lesion. Hypoglossal nerve stimulation via an implantable neurostimulator device is a novel treatment strategy. Patients who continue to have excessive daytime sleepiness despite adequate OSA-specific therapy that is severe enough to warrant treatment may benefit from adjunctive pharmacologic therapy like modafinil and armodafinil. Other drugs have been tried in the management of OSA. In small trials, benefits have been found sporadically with remifentanil, zolpidem, triazolam, eszopiclone, and sodium oxybate. Further large multicentric trials are required to prove their efficacy. There is also a scope for research for thedevelopment of some novel group of drugs for the primary treatment for OSA.


PDF Share
  1. Pien GW, Rosen IM, Fields BG. Sleep apnea syndromes: central and obstructive. In: Fishman's pulmonary diseases and disorders. Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM, Editors. Fishman' pulmonary diseases and disorders. 5th ed McGraw-Hill New York: 2015:1510- 1550.
  2. Qaseem A, Holty JE, Owens DK, et al. Management of obstructive sleep apnea in adults: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013; 159:471.
  3. Chirinos JA, Gurubhagavatula I, Teff K, et al. CPAP, weight loss, or both for obstructive sleep apnea. N Engl J Med 2014; 370:2265.
  4. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284:3015.
  5. Tuomilehto H, Seppä J, Uusitupa M, et al. Weight reduction and increased physical activity to prevent the progression of obstructive sleep apnea: A 4-year observational post intervention follow-up of a randomized clinical trial. JAMA Intern Med 2013; 173:929.
  6. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet 2014; 383:736.
  7. Bratton DJ, Gaisl T, Schlatzer C, Kohler M. Comparison of the effects of continuous positive airway pressure and mandibular advancement devices on sleepiness in patients with obstructive sleep apnoea: a network meta-analysis. Lancet Respir Med 2015; 3:869.
  8. Certal VF, Zaghi S, Riaz M, et al. Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: A systematic review and meta-analysis. Laryngoscope 2015; 125:1254.
  9. Randerath WJ, Verbraecken J, Andreas S, et al. Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J 2011; 37:1000.
  10. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs 2008; 68(13):1803-39.
  11. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007; 101(3):616-27.
  12. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: A 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther. 2006, 28(5): 689-706.
  13. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil)for the treatment of fatigue in multiple sclerosis: a two-centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72(2):179-183.
  14. Schwartz JR. Modafinil in the Treatment of Excessive Sleepiness. Drug Des Devel Ther. 2009; 2:71-85.
  15. USmodafinil in Narcolepsy Multicenter Study Group. Randomized Trial of Modafinil for the Treatment of Pathological Somnolence in Narcolepsy. Ann Neurol, 1998, 43(1):88-97.
  16. Wong YN. Single-dose pharmacokinetics of modafinil and methylphenidate givenalone or in combination in healthy male volunteers. J Clin Pharmacol. 1998; 38(3):276-282.
  17. Mason M, Welsh EJ, Smith I.Drug therapy for obstructive sleep apnoea in adults. Cochrane Database of Systematic Reviews 2013; Issue 5. Art. No.: CD003002. DOI: 10.1002/14651858.CD003002.pub3.
  18. Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database of Systematic Reviews 2015; Issue 7. Art. No.: CD011090. DOI: 10.1002/14651858.CD011090.pub2.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.